BioSpace News Archive

Mesoblast Limited announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.

Ionis Pharmaceuticals, Inc. announced today that it will present positive Phase 3 Balance results in patients with familial chylomicronemia syndrome (FCS) for the company’s lead independent, investigational medicine, olezarsen, at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia.

NRx Pharmaceuticals, Inc. today announced that Dr. Jonathan Javitt , Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024.

Lumicell Inc highlights presentations from clinical studies examining the use of investigational LUMISIGHT™ (pegulicianine) in combination with Lumicell™ Direct Visualization System (DVS) at the Society of Surgical Oncology Annual Meeting in Atlanta, Georgia, March 20-23, 2024.

ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC).

Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticles Targeting safer and accessible mRNA vaccines Altamira Therapeutics Ltd.

ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial investigating PLX038 (PEG~SN-38) for locally-advanced or metastatic triple-negative breast cancer (TNBC).

GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins (SGLT2 and SGLT1), will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia.

SAB Biotherapeutics, Inc. today announced that the Navy Medical Research Command (NMRC) is moving forward with a safety and tolerability study to evaluate SAB-176.